|FDA Clinical Phase:
SNS01-T is a small inhibitory RNA molecule that blocks the expression of Factor 5A mRNA. The Factor 5A gene has been shown to regulate the expression of genes required for programmed cell death. SNS01-T is currently being developed for treatment of multiple myeloma for its potential to induce programmed cell death in cancerous cells.
For a list of clinical trials studying SNS01-T for the treatment of multiple myeloma, see ClinicalTrials.gov.